Parkinson's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Parkinson's Disease, including details on symptoms, treatment, genetics, medication.

Volume 4 (2007), Issue 5 (May)

1. Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease.
   Neurology, 68(18): 1455-9. [Abstract] [Full-text]
2. Nonphysicians' and physicians' knowledge and care preferences for Parkinson's disease.
   Mov Disord, 22(5): 704-7. [Abstract] [Full-text]
3. Malignant melanoma in early Parkinson's disease: the DATATOP trial.
   Mov Disord, 22(5): 720-2. [Abstract] [Full-text]
4. Effects of caffeine on the freezing of gait in Parkinson's disease.
   Mov Disord, 22(5): 710-2. [Abstract] [Full-text]
5. Olfactory loss may be a first sign of idiopathic Parkinson's disease.
   Mov Disord, 22(6): 839-42. [Abstract] [Full-text]
6. Self-reported adherence versus pill count in Parkinson's disease: the NET-PD experience.
   Mov Disord, 22(6): 822-7. [Abstract] [Full-text]
7. Radicular and nonradicular back pain in Parkinson's disease: a controlled study.
   Mov Disord, 22(6): 853-6. [Abstract] [Full-text]
8. Sweating in Parkinsonian patients with wearing-off.
   Mov Disord, 22(6): 828-32. [Abstract] [Full-text]
9. Effect of medical and surgical interventions on health-related quality of life in Parkinson's disease.
   Mov Disord, 22(6): 757-65. [Abstract] [Full-text]
10. Predicting the cost of Parkinson's disease.
    Mov Disord, 22(6): 804-12. [Abstract] [Full-text]
11. Interhemispheric and ipsilateral connections in Parkinson's disease: relation to mirror movements.
    Mov Disord, 22(6): 813-21. [Abstract] [Full-text]
12. The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: a double blind placebo-controlled pilot study.
    Mov Disord, 22(6): 880-3. [Abstract] [Full-text]
13. Higher nigrostriatal dopamine neuron loss in early than late onset Parkinson's disease?--a [99mTc]-TRODAT-1 SPECT study.
    Mov Disord, 22(6): 863-6. [Abstract] [Full-text]
14. Characteristics of apathy in Parkinson's disease.
    Mov Disord, 22(6): 778-84. [Abstract] [Full-text]
15. Effects of loudness cues on respiration in individuals with Parkinson's disease.
    Mov Disord, 22(5): 651-9. [Abstract] [Full-text]
16. Smoking and cognitive function in Parkinson's disease.
    Mov Disord, 22(5): 660-5. [Abstract] [Full-text]
17. Depression symptoms in movement disorders: comparing Parkinson's disease, dystonia, and essential tremor.
    Mov Disord, 22(5): 666-72. [Abstract] [Full-text]
18. Simple clinical tests may predict severe oropharyngeal dysphagia in Parkinson's disease.
    Mov Disord, 22(5): 640-4. [Abstract] [Full-text]
19. Stimulation of subthalamic fibre tracts reduces dyskinesias in STN-DBS.
    Mov Disord, 22(5): 679-84. [Abstract] [Full-text]
20. Number of children and risk of Parkinson's disease.
    Mov Disord, 22(5): 632-9. [Abstract] [Full-text]
21. Data protection in biomaterial banks for Parkinson's disease research: the model of GEPARD (Gene Bank Parkinson's Disease Germany).
    Mov Disord, 22(5): 611-8. [Abstract] [Full-text]
22. Laryngeal electromyography in adults with Parkinson's disease and voice complaints.
    Laryngoscope, 117(5): 831-4. [Abstract] [Full-text]
23. The management of psychosis in movement disorder patients.
    Expert Opin Pharmacother, 8(7): 935-43. [Abstract] [Full-text]
24. Semantic and affective priming as a function of stimulation of the subthalamic nucleus in Parkinson's disease.
    Brain, 130: 1395-407. [Abstract] [Full-text]
25. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease.
    Trends Neurosci, 30(5): 244-50. [Abstract] [Full-text]
26. Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease.
    J Neurosci, 27(18): 4832-8. [Abstract] [Full-text]
27. The etiopathogenesis of Parkinson disease and suggestions for future research. Part II.
    J Neuropathol Exp Neurol, 66(5): 329-36. [Abstract] [Full-text]
28. Nicotine neuroprotection against nigrostriatal damage: importance of the animal model.
    Trends Pharmacol Sci, 28(5): 229-35. [Abstract] [Full-text]
29. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease.
    Neurology, 68(19): 1557-62. [Abstract] [Full-text]
30. Cerebral compensation during motor imagery in Parkinson's disease.
    Neuropsychologia, 45(10): 2201-15. [Abstract] [Full-text]
31. Role of working memory components in planning performance of individuals with Parkinson's disease.
    Neuropsychologia, 45(10): 2393-7. [Abstract] [Full-text]
32. Destabilization of DJ-1 by familial substitution and oxidative modifications: implications for Parkinson's disease.
    Biochemistry, 46(19): 5776-89. [Abstract] [Full-text]
33. Therapeutic rewiring by means of desynchronizing brain stimulation.
    Biosystems, 89(1): 173-81. [Abstract] [Full-text]
34. Advances in the pharmacologic management of early Parkinson disease.
    Neurologist, 13(3): 126-32. [Abstract] [Full-text]
35. Therapeutic approaches to inflammation in neurodegenerative disease.
    Curr Opin Neurol, 20(3): 351-7. [Abstract] [Full-text]
36. Effects of engrafted neural stem cells derived from GFP transgenic mice in Parkinson's diseases rats.
    Neurosci Lett, 419(1): 49-54. [Abstract] [Full-text]
37. Microarray analysis of oxidative stress regulated genes in mesencephalic dopaminergic neuronal cells: relevance to oxidative damage in Parkinson's disease.
    Neurochem Int, 50(6): 834-47. [Abstract] [Full-text]
38. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease.
    Arch Neurol, 64(5): 676-82. [Abstract] [Full-text]
39. Expression of alpha-synuclein, a presynaptic protein implicated in Parkinson's disease, in erythropoietic lineage.
    Biochem Biophys Res Commun, 358(1): 104-10. [Abstract] [Full-text]
40. Cortical cholinergic denervation is associated with depressive symptoms in Parkinson's disease and parkinsonian dementia.
    J Neurol Neurosurg Psychiatry, 78(6): 641-3. [Abstract] [Full-text]
41. G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies.
    J Neurol Neurosurg Psychiatry, 78(6): 626-8. [Abstract] [Full-text]
42. Levodopa slows prosaccades and improves antisaccades: an eye movement study in Parkinson's disease.
    J Neurol Neurosurg Psychiatry, 78(6): 565-70. [Abstract] [Full-text]
43. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial.
    Lancet Neurol, 6(6): 513-20. [Abstract] [Full-text]
44. The error negativity in nonmedicated and medicated patients with Parkinson's disease.
    Clin Neurophysiol, 118(6): 1223-9. [Abstract] [Full-text]
45. Fibroblast growth factor 20 gene and Parkinson's disease in the Japanese population.
    Neuroreport, 18(9): 937-40. [Abstract] [Full-text]
46. Individual dopaminergic neurons show raised iron levels in Parkinson disease.
    Neurology, 68(21): 1820-5. [Abstract] [Full-text]
47. Non-steroidal anti-inflammatory drugs in Parkinson's disease.
    Exp Neurol, 205(2): 295-312. [Abstract] [Full-text]
48. Hypocretin (orexin) cell loss in Parkinson's disease.
    Brain, 130: 1586-95. [Abstract] [Full-text]
49. Hypocretin (orexin) loss in Parkinson's disease.
    Brain, 130: 1577-85. [Abstract] [Full-text]
50. Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease.
    Mol Genet Metab, 91(2): 195-200. [Abstract] [Full-text]
51. Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease.
    Brain, 130: 1596-607. [Abstract] [Full-text]
52. The proteasomal subunit S6 ATPase is a novel synphilin-1 interacting protein--implications for Parkinson's disease.
    FASEB J, 21(8): 1759-67. [Abstract] [Full-text]
53. Multifunctional tellurium molecule protects and restores dopaminergic neurons in Parkinson's disease models.
    FASEB J, 21(8): 1870-83. [Abstract] [Full-text]

© 2004-2008 Parkinson's Disease Research Today. All Rights Reserved.